Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Driessen (Brentford, United Kingdom). Cost-effectiveness of umeclidinium bromide 62.5µg or alternative LAMA plus ICS/LABA in COPD. 2789

Member's Comments

No comment yet.

Related content which might interest you: Cost effectiveness of umeclidinium bromide 62.5µg plus ICS/LABA versus ICS/LABA in COPD Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Maintenance plus as-needed budesonide/formoterol is cost-effective compared with dose-titrated salmeterol/fluticasone Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005 Tiotropium bromide (TIO) reduces hospitalizations in patients with COPD who had been refractory to treatment with combined inhaled corticosteroid/long acting beta agonist (ICS/LABA) Source: Eur Respir J 2005; 26: Suppl. 49, 717s Year: 2005 Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005 Sequential flexible therapy with formoterol (Foradil®) plus budesonide (Miflonide®) versus a fixed combination of salmeterol and fluticasone (Seretide®) in asthma self-management Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002 Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Financial benefits of fluticasone propionate/salmeterol 250/50 mcg fixed dose combination over tiotropium in elderly managed COPD patient Source: Annual Congress 2010 - Management of airway disease Year: 2010 Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012 The potential cost-effectiveness of glycopyrronium bromide, a novel LAMA Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler Source: ERJ Open Res 2016: 00106-2015 Year: 2016 Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001 Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) Source: Eur Respir J 2015; 45: 969-979 Year: 2015 Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe COPD in France Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017